Related Experiment Videos
Prospective randomized studies are needed to define the role of axillary lymph node dissection in primary breast
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.
Annals of oncology : official journal of the European Society for Medical Oncology·2021
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
Annals of oncology : official journal of the European Society for Medical Oncology·2019
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Annals of oncology : official journal of the European Society for Medical Oncology·2018
Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
Breast cancer research and treatment·2017
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2017
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.
Breast cancer research and treatment·2017
Purple Blossoms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Pre-operative circulating tumour DNA in high-risk primary cutaneous melanoma: prospective feasibility in molecular pathology.
Acta oncologica (Stockholm, Sweden)·2026
Integrating genetic predictors into subsequent breast cancer risk prediction in survivors of childhood cancer.
Journal of the National Cancer Institute·2026
Predicting pancreatic cancer in high-risk individuals and in the general population: how long is the road yet?
Revista espanola de enfermedades digestivas·2026